Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Upgraded by Hsbc Global Res

Hsbc Global Res upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Free Report) from a hold rating to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

Several other research firms have also issued reports on BAYRY. The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Wall Street Zen raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Finally, Kepler Capital Markets raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of "Buy".

Bayer Aktiengesellschaft Stock Performance

Bayer Aktiengesellschaft stock traded down $0.16 during midday trading on Wednesday, hitting $7.87. 385,705 shares of the company were exchanged, compared to its average volume of 807,125. The business has a fifty day simple moving average of $6.62 and a two-hundred day simple moving average of $5.93. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The firm has a market capitalization of $30.93 billion, a PE ratio of -30.27 and a beta of 0.85. Bayer Aktiengesellschaft has a fifty-two week low of $4.79 and a fifty-two week high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.02. The business had revenue of $15.27 billion for the quarter, compared to analysts' expectations of $13.39 billion. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. On average, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th were issued a dividend of $0.0224 per share. This represents a yield of 0.38%. This is an increase from Bayer Aktiengesellschaft's previous dividend of $0.02. The ex-dividend date was Tuesday, April 29th. Bayer Aktiengesellschaft's dividend payout ratio (DPR) is presently -2.17%.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.